Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines.
PEG
complement
mRNA vaccines
nanoparticles
safe-by-design
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
02
2022
accepted:
09
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Poly (ethylene glycol) (PEG) is a widely used polymer in a variety of consumer products and in medicine. PEGylation refers to the conjugation of PEG to drugs or nanoparticles to increase circulation time and reduce unwanted host responses. PEG is viewed as being well-tolerated, but previous studies have identified anti-PEG antibodies and so-called pseudoallergic reactions in certain individuals. The increased use of nanoparticles as contrast agents or in drug delivery, along with the introduction of mRNA vaccines encapsulated in PEGylated lipid nanoparticles has brought this issue to the fore. Thus, while these vaccines have proven to be remarkably effective, rare cases of anaphylaxis have been reported, and this has been tentatively ascribed to the PEGylated carriers, which may trigger complement activation in susceptible individuals. Here, we provide a general overview of the use of PEGylated nanoparticles for pharmaceutical applications, and we discuss the activation of the complement cascade that might be caused by PEGylated nanomedicines for a better understanding of these immunological adverse reactions.
Identifiants
pubmed: 35747492
doi: 10.3389/fbioe.2022.882363
pii: 882363
pmc: PMC9209764
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
882363Informations de copyright
Copyright © 2022 Padín-González, Lancaster, Bottini, Gasco, Tran, Fadeel, Wilkins and Monopoli.
Déclaration de conflit d'intérêts
PG is the CEO of Nanovector Srl, an SME that develops nanomaterials for health applications. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Colloid Interface Sci. 2022 May;613:563-574
pubmed: 35066229
J Pharmacol Exp Ther. 2000 Mar;292(3):1071-9
pubmed: 10688625
Adv Exp Med Biol. 2013;735:207-18
pubmed: 23402029
Nat Commun. 2017 Dec 12;8(1):2078
pubmed: 29233958
ACS Appl Mater Interfaces. 2020 Jul 15;12(28):31172-31181
pubmed: 32532159
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):655-77
pubmed: 25707913
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
J Pharm Sci. 2008 Oct;97(10):4167-83
pubmed: 18200508
J Biol Chem. 1977 Jun 10;252(11):3578-81
pubmed: 405385
JAMA Netw Open. 2021 Sep 1;4(9):e2125524
pubmed: 34533570
J Immunol Methods. 2015 Feb;417:86-96
pubmed: 25536073
Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1691-702
pubmed: 25270687
J Mol Biol. 1965 Aug;13(1):238-52
pubmed: 5859039
Anal Chem. 2016 Nov 1;88(21):10661-10666
pubmed: 27726379
Vaccines (Basel). 2021 Aug 03;9(8):
pubmed: 34451973
ACS Nano. 2021 Jun 28;:
pubmed: 34181394
Ann Oncol. 2003 Sep;14(9):1430-7
pubmed: 12954584
J Pharmacol Exp Ther. 2005 Mar;312(3):1020-6
pubmed: 15525796
Nat Nanotechnol. 2017 Jul;12(6):589-594
pubmed: 28396605
J Allergy Clin Immunol. 2021 Jun;147(6):2075-2082.e2
pubmed: 33857566
Biomaterials. 1990 Sep;11(7):521-4
pubmed: 2242403
Nature. 2021 Sep;597(7876):318-324
pubmed: 34522017
J Allergy Clin Immunol. 2002 Apr;109(4):658-68
pubmed: 11941316
J Biol Chem. 1977 Jun 10;252(11):3582-6
pubmed: 16907
Nanomedicine. 2019 Apr;17:266-275
pubmed: 30794962
Adv Sci (Weinh). 2021 Jun;8(11):e2004506
pubmed: 34105291
iScience. 2021 Dec 17;24(12):103479
pubmed: 34841223
Vaccine. 2021 May 6;39(19):2605-2607
pubmed: 33846043
Vaccines (Basel). 2021 Jan 19;9(1):
pubmed: 33478109
Nanomaterials (Basel). 2020 Apr 20;10(4):
pubmed: 32325941
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51
pubmed: 33444297
Vaccines (Basel). 2021 Aug 31;9(9):
pubmed: 34579211
J Control Release. 2007 Jun 4;119(2):236-44
pubmed: 17399838
Medchemcomm. 2019 Feb 12;10(3):369-377
pubmed: 31015904
J Pharm Sci. 1994 Apr;83(4):601-6
pubmed: 8046623
Chem Soc Rev. 2015 Oct 7;44(17):6094-121
pubmed: 26065524
Nanoscale. 2021 Mar 21;13(11):5883-5891
pubmed: 33725081
J Immunol. 1978 Oct;121(4):1232-8
pubmed: 100552
Biochem Pharmacol. 1989 Jan 1;38(1):73-6
pubmed: 2642704
Nat Nanotechnol. 2016 Apr;11(4):372-7
pubmed: 26878141
Materials (Basel). 2020 Oct 13;13(20):
pubmed: 33066064
Nat Rev Mater. 2021;6(12):1078-1094
pubmed: 34394960
Nat Nanotechnol. 2021 Nov;16(11):1169-1171
pubmed: 34732846
Int J Nanomedicine. 2019 Mar 25;14:2055-2067
pubmed: 30988608
Biomacromolecules. 2016 May 9;17(5):1757-65
pubmed: 27046506
Adv Drug Deliv Rev. 2020;154-155:163-175
pubmed: 32745496
Int J Pharm. 2008 Apr 16;354(1-2):56-62
pubmed: 18083313
J Am Chem Soc. 2010 Jul 7;132(26):8844-5
pubmed: 20536128
Allergy Asthma Clin Immunol. 2021 Oct 16;17(1):109
pubmed: 34656181
Expert Opin Drug Deliv. 2016 Sep;13(9):1257-75
pubmed: 27116988
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129
pubmed: 33507892
Anal Chem. 2016 Dec 6;88(23):11804-11812
pubmed: 27804292
Prog Lipid Res. 2003 Nov;42(6):463-78
pubmed: 14559067
BMC Biophys. 2012 Aug 08;5:14
pubmed: 22873343
Nanomedicine. 2012 Feb;8(2):176-84
pubmed: 21704590
Clin Nurs Res. 2016 Oct;25(5):549-59
pubmed: 25784149
Colloids Surf B Biointerfaces. 2000 Oct 1;18(3-4):301-313
pubmed: 10915952
J Pharm Sci. 2016 Feb;105(2):460-475
pubmed: 26869412
Nano Today. 2015 Aug;10(4):487-510
pubmed: 26640510
Nano Today. 2017 Aug;15:8-10
pubmed: 29399037
Bioconjug Chem. 2008 Apr;19(4):973-81
pubmed: 18380471
Front Immunol. 2020 Feb 14;11:222
pubmed: 32117324
Pharm Res. 2013 Jul;30(7):1729-34
pubmed: 23673554
Blood. 2022 Apr 29;:
pubmed: 35486845
Adv Mater. 2019 Jan;31(4):e1803335
pubmed: 30488990
Int J Pharm. 2021 May 15;601:120586
pubmed: 33839230
Biomaterials. 2011 Oct;32(28):6791-803
pubmed: 21724247
Nat Commun. 2021 Dec 13;12(1):7233
pubmed: 34903741
Theranostics. 2018 May 9;8(11):3164-3175
pubmed: 29896310
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1731-1733.e3
pubmed: 33217616
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Nov;13(6):e1738
pubmed: 34254460
ACS Nano. 2015 Jul 28;9(7):6996-7008
pubmed: 26079146
Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1319-28
pubmed: 10993799
Expert Opin Drug Deliv. 2012 Nov;9(11):1319-23
pubmed: 22931049
Nat Nanotechnol. 2012 Dec;7(12):779-86
pubmed: 23212421
Nano Lett. 2021 Feb 24;21(4):1591-1598
pubmed: 33560851
J Colloid Interface Sci. 2021 May;589:453-461
pubmed: 33485252
CMAJ. 2021 Dec 6;193(48):E1842
pubmed: 34772737
Mol Ther. 2021 Mar 3;29(3):898-900
pubmed: 33571463
ACS Nano. 2020 Sep 22;14(9):11950-11961
pubmed: 32845615
Clin Infect Dis. 2022 Jun 10;74(11):1933-1950
pubmed: 34406358
J Am Chem Soc. 2011 Mar 2;133(8):2525-34
pubmed: 21288025
ACS Nano. 2013 Mar 26;7(3):1974-89
pubmed: 23413928
Int Arch Allergy Appl Immunol. 1983;70(2):124-31
pubmed: 6401699
J Control Release. 2003 Feb 14;88(1):35-42
pubmed: 12586501
ACS Nano. 2019 Aug 27;13(8):9315-9324
pubmed: 31348638
Biomaterials. 2009 Apr;30(12):2231-40
pubmed: 19167749
ACS Nano. 2010 Nov 23;4(11):6629-38
pubmed: 21028845
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
ACS Nano. 2017 Aug 22;11(8):7572-7586
pubmed: 28727419
J Am Chem Soc. 2012 Feb 1;134(4):2139-47
pubmed: 22191645
Adv Drug Deliv Rev. 2020;158:91-115
pubmed: 32598970
Nano Lett. 2020 Jun 10;20(6):4312-4321
pubmed: 32259451
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8399-404
pubmed: 9237988
Drug Saf. 2021 Nov;44(11):1209-1214
pubmed: 34347278
Mol Immunol. 2014 Oct;61(2):163-73
pubmed: 25124145
Pharmaceutics. 2010 Dec 27;3(1):1-11
pubmed: 24310423
Adv Drug Deliv Rev. 2011 Sep 16;63(12):1020-30
pubmed: 21787819
Drug Discov Today. 2018 May;23(5):1034-1042
pubmed: 29146517
J Control Release. 2014 Oct 28;192:67-81
pubmed: 24997275
Eur J Immunol. 1993 Jul;23(7):1719-22
pubmed: 8325342
Geroscience. 2022 Apr;44(2):597-618
pubmed: 35146583
Langmuir. 2011 Jun 7;27(11):6794-800
pubmed: 21528934
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
Invest Radiol. 1976 Jul-Aug;11(4):303-8
pubmed: 955839
Nat Rev Drug Discov. 2003 Mar;2(3):214-21
pubmed: 12612647
Nat Nanotechnol. 2019 Mar;14(3):260-268
pubmed: 30643271
Sci Technol Adv Mater. 2019 Jun 26;20(1):710-724
pubmed: 31275462
J Pharmacol Exp Ther. 2019 Sep;370(3):581-592
pubmed: 30940695
Theranostics. 2020 May 17;10(15):6695-6714
pubmed: 32550898
Toxicol Appl Pharmacol. 1982 Sep 15;65(2):329-35
pubmed: 7179288
Int Arch Allergy Appl Immunol. 1984;74(1):36-9
pubmed: 6706424
Angew Chem Int Ed Engl. 2015 Mar 16;54(12):3763-7
pubmed: 25655646
Nat Nanotechnol. 2021 Aug;16(8):843-850
pubmed: 34381200
Biochem J. 1971 Oct;124(5):58P
pubmed: 5130994
Nat Commun. 2017 Feb 24;8:14537
pubmed: 28233871
Nat Nanotechnol. 2017 May;12(4):387-393
pubmed: 27992410
Cancer. 2007 Jul 1;110(1):103-11
pubmed: 17516438
Allergy. 2021 Nov;76(11):3307-3313
pubmed: 33657648
Angew Chem Int Ed Engl. 2010 Aug 23;49(36):6288-308
pubmed: 20648499
Toxicology. 2005 Dec 15;216(2-3):106-21
pubmed: 16140450
Nat Mater. 2009 Jul;8(7):543-57
pubmed: 19525947
Adv Drug Deliv Rev. 2022 Jan;180:114079
pubmed: 34902516
Clin Exp Allergy. 2016 Jul;46(7):907-22
pubmed: 27196817
J Cell Commun Signal. 2019 Sep;13(3):319-330
pubmed: 30499020
J Allergy Clin Immunol Pract. 2021 Oct;9(10):3546-3567
pubmed: 34153517
Lancet. 2021 Jan 30;397(10272):355-357
pubmed: 33453149
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2050-5
pubmed: 17267609
Biomaterials. 2005 May;26(13):1477-85
pubmed: 15522749